HOME > BUSINESS
BUSINESS
- Japan Becomes World No. 2 Vaccine Market Pushed by HPV Vaccines
July 4, 2012
- Sanofi, Hisamitsu Set Up Joint Venture with Sanofi Chief as President and Chairman
July 4, 2012
- AnGes MG to License Exclusive US Marketing Rights for Collategene to MTPC
July 4, 2012
- 230 MSs of Mediceo Begin to Work as ARs for Sawai
July 4, 2012
- COPD Treatment Oxis Approved, to Be Marketed by Meiji Seika Pharma: AZ
July 4, 2012
- Taisho Makes Tokuhon Wholly Owned Subsidiary; Expanding Business in Topical, Adhesive Agents
July 4, 2012
- Over 60% of Meiji Seika Pharma’s Generics Have Top 3 Market Share: GM Umeki
July 3, 2012
- Nippon Kayaku in Final Preparatory Stage for NK105 PIII Trials: Managing Director Suzuki
July 3, 2012
- Japan’s 5th DPP-4 Inhibitor Tenelia Approved: MTPC
July 3, 2012
- Otsuka, Kyowa Kirin Announce Strategic Alliance in Fields of Diabetes, Oncology
July 2, 2012
- Astellas Receives Approval for Prostate Cancer Treatment Gonax
July 2, 2012
- Toyama Chemical, Eisai Receive Approval for Anti-Rheumatic Treatment, to Market under 2 Brands
July 2, 2012
- Takeda Initiates International PIII Trial of Velcade Successor
July 2, 2012
- Mirabegron Approved in the US: Astellas
July 2, 2012
- Anti-Obesity Agent Belviq Approved in US, to Be Launched in Jan. 2013: Eisai
July 2, 2012
- Merck Serono No. 1 in Infertility Treatment Market through Ninkatsu Image Strategy
July 2, 2012
- M3, Mediscience, MIC Medical Consider Capital, Operational Alliance to Establish 650 CRAs Structure
June 29, 2012
- Teva Pharma to Streamline Overlapping Products in 3 years: President Shimada
June 29, 2012
- Bayer Yakuhin to Transfer 3 Established Products to FFP
June 29, 2012
- NDA Filed for Gout Treatment Topiroxostat: Fuji Yakuhin, Sanwa Kagaku
June 29, 2012
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…